
    
      The current study was conducted in the Clinics of Oral Medicine, Faculty of Dentistry and
      Rheumatology, Faculty of Medicine - Cairo University from 2017 to 2019. This study followed
      the principles of the Helsinki Declaration and was approved by the Research ethics committee
      of Faculty of Dentistry, Cairo University.

      RA patients receiving MTX as monotherapy were included in the study. Patients suffering from
      systemic disease known to cause oral manifestations; salivary gland diseases and malignancies
      were excluded.

      All eligible patients were subjected to thorough clinical examination for the whole oral
      cavity. Medical history and history of any oral manifestation were recorded. Drug history,
      dose, and duration of MTX were recorded.

      Categorical data was presented as frequencies and percentages. Continuous data was described
      as means and standard deviations. Means were compared by one-way ANNOVA and Student-t-test.
      The significance level was set at P ≤0.05. Statistical analysis was performed with IBM® SPSS®
      Statistics Version 25 for Windows.
    
  